You're taking Mounjaro and not losing weight — here's what that usually means

You started, you waited, and the number barely moved

Picture the first four or eight weeks. You've followed the injection schedule, you're vaguely eating less (because the appetite suppression is real even if subtle) and then you step on the scales and feel cheated. This is one of the most common experiences our prescribers hear about, and the explanation is almost always the same: 2.5mg is not a dose built for weight loss. Its job is to settle your system into the medicine. The nausea, the adjustment, the way your gut responds to a new mechanism, the starting dose manages all of that before your body is ready to respond therapeutically.

The timeline for Mounjaro to produce visible results typically runs longer than most people expect. Significant loss in SURMOUNT-1 (the pivotal trial cited by NICE in its tirzepatide appraisal (TA1026)) accumulated over 72 weeks, with participants on the higher doses seeing the largest effects. If you're two weeks in on the starter pen, you are not behind schedule. You're at the beginning of a process, not stuck in the middle of a failure.

There's also a practical timing question worth acknowledging: people often start a new treatment at an imperfect moment, over Christmas, before a holiday, around a period of high stress. The medicine doesn't know it's Easter. External factors do influence results, and they're worth naming honestly rather than blaming yourself or the drug.

The scales might be lying to you about fat loss

Body weight is not the same as body fat. This sounds like a cliché until you understand the mechanics behind it. Tirzepatide can cause a shift in how your body handles fluid, particularly in the early weeks. If you've started eating more protein (which is advisable on any GLP-1 treatment to preserve muscle) and doing any resistance activity, you may be building or preserving lean tissue at the same time as losing fat, and muscle is denser than fat. The scales don't distinguish between the two.

For people who menstruate, the cycle alone can account for two to four kilograms of variation across a month. Measuring weight at the same time of day, once a week rather than daily, on the same scales, removes a lot of the noise. A tape measure around the waist often tells a more honest story than the number on the floor, particularly in the first couple of months.

If you want more context on the patterns people see, the guide on why you might not be losing any weight on Mounjaro covers the physiology in more detail. The short version: fat loss and scale movement are correlated but not identical, and the gap between them can feel deeply unfair.

When diet and dose are the more likely explanation

Tirzepatide works by reducing appetite through dual GIP and GLP-1 receptor activity, it makes eating less feel natural, not forced. But it doesn't make excess calories disappear. Some people find that the appetite suppression at lower doses is mild enough that they compensate without realising: slightly larger portions, snacking out of habit rather than hunger, or drinking calorie-dense drinks they haven't counted. The NHS patient information page for tirzepatide notes that treatment works best alongside a reduced-calorie diet and increased activity, not instead of them.

The other dose-related reality is that results tend to track with dose. People on 10mg or 15mg consistently show larger average losses than those on 5mg. If you have been on the same dose for several months without progress, that's a clinical conversation, not a reason to stop. A prescriber can assess whether titrating upward is appropriate, whether there are any factors limiting your response, and whether something else needs adjusting. The detailed breakdown of why Mounjaro may not be working covers the dose-response relationship with more granularity.

For context on what the medicine costs at different stages, the Mounjaro cost page is a useful reference if you're weighing up continuing privately.

What genuinely counts as a plateau, and what to do about it

NICE guidance on tirzepatide (TA1026) includes a review point at six months: if someone has lost less than five per cent of their body weight at the highest dose they've tolerated, continuing treatment is formally reconsidered. That is a clinical threshold, not a verdict on personal failure, it exists because the medicine genuinely does not work the same way for everyone.

But six months at a sub-optimal dose is not the same as six months at the maximum. Many people who feel stuck are still mid-titration and haven't yet reached the dose where their individual response kicks in. If you're finding that you're not losing weight on Mounjaro despite following the programme, whether that comes down to your dose, your body's response, or something else entirely, that is exactly the kind of thing a prescriber should assess before any decision is made to pause, stop or switch.

If you're treating yourself as a test case of one, comparing your results to someone else's four-month progress on social media, the comparison is unlikely to be fair. Genetics, starting weight, metabolic history, activity levels, medications and dozens of other variables shape the response. An honest clinical review (looking at your actual trajectory, your current dose, and any relevant factors) is more useful than any forum thread.

The weight-loss treatments page has more detail on how our prescribers approach clinical review, including for patients already on treatment who want a second opinion or a more thorough assessment.